Galmed Pharma (GLMD) Tops Q3 EPS by 6c

Galmed Pharma (NASDAQ: GLMD) reported Q3 EPS of ($0.23), $0.06 better than the analyst estimate of ($0.29).

For earnings history and earnings-related data on Galmed Pharma (GLMD) click here.

You May Also Be Interested In

• Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
• Champions Oncology (CSBR) Tops Q1 EPS by 6c
• Adobe beats Q3 targets, but soft Q4 sales guidance triggers dip